ArticleChemistry & biodiversity2026
Antinociceptive and Anti-Inflammatory Effects of Alchemilla daghestanica and Alchemilla minusculiflora: Quantitative Phytochemical Profiling and In Vivo Evidence.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Inflammatory pain mediated by pro-inflammatory factors remains a major clinical challenge, highlighting the need for safer alternatives to conventional anti-inflammatory drugs. Here, the antinociceptive effects of methanolic extracts from the aerial parts of Alchemilla daghestanica (AD) and Alchemilla minusculiflora (AM) were evaluated in mice using the formalin test, and anti-inflammatory activity was assessed by measuring formalin-induced paw edema. Phytochemical characterization was performed by LC-MS/MS, and potential activities of major constituents were predicted using PASS Online. LC-MS/MS identified miquelianin as the predominant compound in both extracts. AD (100-200 mg/kg) and AM (200 mg/kg) significantly inhibited the inflammatory phase of the formalin test (p < 0.001 and p < 0.01, respectively) without affecting the neurogenic phase, and AM extract reduced paw edema (p < 0.05). PASS predicted high probabilities (Pa > 0.7) for anti-inflammatory activity of miquelianin, isoquercitrin, and tannic acid. These findings suggest that these extracts may represent valuable candidates for further investigation in inflammatory pain management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.